A pivotal global study of AG-348 in adult patients with in pyruvate kinase (PK) deficiency

Trial Profile

A pivotal global study of AG-348 in adult patients with in pyruvate kinase (PK) deficiency

Planning
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs AG 348 (Primary)
  • Indications Haemolytic anaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2017 According to an Agios Pharmaceuticals media release, the company expects to enroll aprox. 80 to 100 patient.
    • 24 Jun 2017 According to an Agios Pharmaceuticals media release, the company expects to initiate the global pivotal development in the first half of 2018.
    • 16 Feb 2017 According to Agios Pharmaceuticals media release, comapny expects to finalize study design in the third quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top